Adherence to Antihyperlipidemic Medication and Lipid Control in Diabetic Veterans Affairs Patients with Psychotic Disorders

Psychosomatics

Volumn 52, Issue 4, 2011, Pages 310-318

  Nelson, Leigh Anne ^a   Graham, Maqual R ^a   Lindsey, Cameron C ^a   Rasu, Rafia S ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ARIPIPRAZOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CONTROL; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SMOKING; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHI SQUARE DISTRIBUTION; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOSIS; VETERAN;

ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; VETERANS;

EID: 84856370240     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2011.03.004     Document Type: Article

References (29)

1. Byerly M.J., Nakonezny P.A., Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007, 30:437-452.
2. Lacro J.P., Dunn L.B., Dolder C.R., et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
3. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity.
4. Harris E.C., Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998, 173:11-53.
5. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997, 171:502-508.
6. Technical Report 16. Alexandria, VA. National Association of State Mental Health Program Directors, Medical Directors Council Measurement of Health Status for People with Serious Mental Illnesses, Accessed October 21, 2010. http://www.nasmhpd.org.
7. Colton C.W., Manderscheid R.W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3:1-12.
8. Keefe R.S.E. Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry 2007, 68(Suppl 14):8-13.
9. Velligan D.I., Weiden P.J., Sajatovic M., et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010, 16:306-324.
10. Kreyenbuhl J., Dixon L.B., McCarthy J.F., et al. Does adherence to medications for type 2 diabetes differ between individuals with vs. without schizophrenia. Schizophr Bull 2010, 36:428-435.
11. Dolder C.R., Furtek K., Lacro J.P., et al. Antihypertensive medication adherence and blood pressure control in patients with psychotic disorders compared with persons without psychiatric illness. Psychosomatics 2005, 46:135-141.
12. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III), Accessed September 23, 2008. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
13. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
14. Standards of Medical Care in Diabetes-2008. American Diabetes Association. Diabetes Care 2008, 31(S1):S12-S54. American Diabetes Association.
15. Texas Medication Algorithm Project (TMAP) A Collaborative Effort, Accessed June 3, 2010. http://www.dshs.state.tx.us/mhprograms/pdf/TIMASCZAlgoAlgorithm.pdf.
16. Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. NIH publication no. 00-4084 2000, Department of Health and Human Services, NIH-NHLBI, National Institutes of Health, Bethesda, MD.
17. Von Korff M., Wagner E.H., Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992, 45:197-203.
18. Putnam K.G., Buist D.S.M., Fishman P., et al. Chronic disease score as a predictor of hospitalization. Epidemiology 2002, 13:340-346.
19. Sikka R., Xia F., Aubert R.E. Estimating medication persistency using administrative claims data. Am J Manag Care 2005, 11:449-457.
20. Steiner J.F., Prchazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and application. J Clin Epidemiol 1997, 50:105-116.
21. Hamilton R.A., Briceland L.L. Use of prescription refill records to assess patient compliance. Am J Hosp Pharm 1992, 49:1691-1696.
22. Dolder C.R., Lacro J.P., Jeste D.V. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003, 65:156-162.
23. Dolder D.R., Lacro J.P., Jeste D.V. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003, 65:156-162.
24. Lacro J.P., Dunn L.B., Dolder C.R., et al. Prevalence and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
25. McCreadie R.G. Diet, smoking, and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003, 183:534-539.
26. Peet M. Diet, diabetes, and schizophrenia: review and hypothesis. Br J Psychiatry 2004, 47:S102-S105.
27. The State of Health Care Quality 2009 National Committee for Quality Assurance, Accessed July 2, 2010. http://www.ncqa.org/Portals/0/Newsroom/SOHC/SOHC_2009.pdf.
28. VA/DOD clinical practice guideline for the management of dyslipidemia, Accessed July 8, 2010. http://www.healthquality.va.gov/lipids/lip05_950_final2.pdf.
29. Dolder C.R., Lacro J.P., Dunn L.B., et al. Medication adherence: is there a difference between typical and atypical agents?. Am J Psychiatry 2002, 159:103-108.